Collegium Pharma beats Q3 revenue estimates, raises guidance

Collegium Pharmaceutical

06/11/2025 12:45

Overview

Collegium Q3 revenue grows 31% yr/yr, beating analyst expectations

Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

Company raises full-year 2025 revenue and adjusted EBITDA guidance

Outlook

Company raises full-year 2025 net revenue guidance to $775-$785 mln

Collegium increases full-year 2025 adjusted EBITDA guidance to $460-$470 mln

Company expects 2025 Jornay PM revenue between $145 mln and $150 mln

Result Drivers

JORNAY PM GROWTH - 20% increase in prescriptions driven by back-to-school season, per CEO Vikram Karnani

PAIN PORTFOLIO EXPANSION - Pain portfolio net revenue grew 11% yr/yr with all core products increasing

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$209.40 mln
$189.12 mln (5 Analysts)
Q3 Adjusted EPS
Beat
$2.25
$2.04 (5 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Collegium Pharmaceutical Inc is $45.00, about 20.3% above its November 5 closing price of $35.85

The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 4 three months ago

Press Release: ID:nGNXtpMWn

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)